Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

被引:4
|
作者
Lin, Shin-Yi [1 ,2 ]
Kuo, Ching-Hua [2 ]
Ho, Li-Ting [3 ,4 ]
Liu, Yen-Bin [3 ,4 ]
Huang, Chih-Fen [1 ,2 ]
Tang, Sung-Chun [5 ,6 ]
Jeng, Jiann-Shing [5 ,6 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Cardiovasc Ctr, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan
关键词
atrial fibrillation; edoxaban; factor Xa inhibitors; therapeutic drug monitoring; Asians; PREDICTING STROKE; PHARMACODYNAMICS; PHARMACOKINETICS; ANTICOAGULANT; WARFARIN; OUTCOMES; RISK;
D O I
10.3389/fphar.2021.736826
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations. Methods: Participants with atrial fibrillation who were undergoing edoxaban therapy were enrolled. Peak (1-4 h after edoxaban administration) and trough (24 +/- 4 h from the last edoxaban dose) blood samples were collected to measure edoxaban concentrations using ultrahigh-performance liquid chromatography with tandem mass spectrometry. The edoxaban concentrations were compared to those observed in clinical trials to define a higher- or lower-than-expected range. Multivariate logistic regression was used to analyze the risk factors associated with high or low edoxaban concentrations. Results: Eighty participants (49 men, 61.3%) were enrolled and provided 78 trough and 76 peak samples. Twenty participants (25.6%) were determined to have low trough concentrations, which was associated with higher creatinine clearance and the use of the 30 mg regimen (odds ratio [OR] and 95% confidence interval [CI], 1.06 [1.01, 1.11], p = 0.01 and 5.77 [1.34, 24.75], p = 0.02, respectively). In contrast, 21 participants (27.6%) had high peak concentrations, which was associated with an off-label overdosing regimen (OR = 4.68 [1.23, 17.70], p = 0.02). Conclusion: Our study identified factors associated with increased or decreased edoxaban exposure. The measurement of edoxaban concentration may be recommended for patients with selected characteristics.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Edoxaban versus Warfarin in Patients with Atrial Fibrillation
    Giugliano, Robert P.
    Ruff, Christian T.
    Braunwald, Eugene
    Murphy, Sabina A.
    Wiviott, Stephen D.
    Halperin, Jonathan L.
    Waldo, Albert L.
    Ezekowitz, Michael D.
    Weitz, Jeffrey I.
    Spinar, Jindrich
    Ruzyllo, Witold
    Ruda, Mikhail
    Koretsune, Yukihiro
    Betcher, Joshua
    Shi, Minggao
    Grip, Laura T.
    Patel, Shirali P.
    Patel, Indravadan
    Hanyok, James J.
    Mercuri, Michele
    Vogelmann, O.
    Gonzalez, C.
    Ahuad Guerrero, R.
    Rodriguez, M.
    Albisu, J.
    Rosales, E.
    Allall, O.
    Reguero, M.
    Alvarez, C.
    Garcia, M.
    Ameriso, S.
    Ameriso, P.
    Amuchastegui, M.
    Caceres, M.
    Beloscar, J.
    Petrucci, J.
    Berli, M.
    Budassi, N.
    Valle, M.
    Bustamante Labarta, G.
    Saravia, M.
    Caccavo, A.
    Fracaro, V.
    Cartasegna, L.
    Novas, V.
    Caruso, O.
    Saa Zarandon, R.
    Colombo, H.
    Morandini, M.
    Cuello, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22): : 2093 - 2104
  • [2] Edoxaban for the prevention of stroke in patients with atrial fibrillation
    Escobar Cervantes, Carlos
    Luis Merino, Jose
    Barrios, Vivencio
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (04) : 319 - 330
  • [3] Edoxaban versus Warfarin in patients with atrial fibrillation
    Meras Colunga, P.
    REVISTA CLINICA ESPANOLA, 2014, 214 (06): : 346 - 346
  • [4] Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
    Takeru Nabeta
    Keisuke Kida
    Miwa Ishida
    Takaaki Shiono
    Norio Suzuki
    Shunichi Doi
    Maya Tsukahara
    Yuki Ohta
    Tetsuya Kimura
    Keita Yamaguchi
    Atsushi Takita
    Naoki Matsumoto
    Yoshihiro J. Akashi
    Junya Ako
    Takayuki Inomata
    Clinical Pharmacokinetics, 2021, 60 : 1061 - 1071
  • [5] Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
    Nabeta, Takeru
    Kida, Keisuke
    Ishida, Miwa
    Shiono, Takaaki
    Suzuki, Norio
    Doi, Shunichi
    Tsukahara, Maya
    Ohta, Yuki
    Kimura, Tetsuya
    Yamaguchi, Keita
    Takita, Atsushi
    Matsumoto, Naoki
    Akashi, Yoshihiro J.
    Ako, Junya
    Inomata, Takayuki
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1061 - 1071
  • [6] Factors Associated with Anticoagulant Treatment Among Medicare Patients With Atrial Fibrillation
    Chen, S.
    Vanderpoel, J.
    Boulanger, L.
    Rao, P.
    Nelson, W. W.
    Schein, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 : S127 - S128
  • [7] Factors associated with depression and anxiety among caregivers of patients with atrial fibrillation
    Li, Sitong
    Li, Qifan
    Jiang, Chao
    Chen, Xuan
    Lai, Yiwei
    He, Liu
    Cui, Feihuan
    Wu, Jiahui
    Hu, Rong
    Jia, Changqi
    Feng, Li
    Sang, Caihua
    Tang, Ribo
    Long, Deyong
    Du, Xin
    Dong, Jianzeng
    Ma, Changsheng
    JOURNAL OF CLINICAL NURSING, 2022, 31 (21-22) : 3263 - 3271
  • [8] Edoxaban in Asian Patients With Atrial Fibrillation Effectiveness and Safety
    Lee, So-Ryoung
    Choi, Eue-Keun
    Han, Kyung-Do
    Jung, Jin-Hyung
    Oh, Seil
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (08) : 838 - 853
  • [9] Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
    Carnicelli, Anthony P.
    De Caterina, Raffaele
    Halperin, Jonathan L.
    Renda, Giulia
    Ruff, Christian T.
    Trevisan, Marco
    Nordio, Francesco
    Mercuri, Michele F.
    Antman, Elliott
    Giugliano, Robert P.
    CIRCULATION, 2017, 135 (13) : 1273 - 1275
  • [10] Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment
    Koretsune, Y.
    Yamashita, T.
    Yasaka, M.
    EUROPEAN HEART JOURNAL, 2013, 34 : 95 - 95